Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/66—Microorganisms or materials therefrom
  • A61K35/74—Bacteria
  • A61K35/741—Probiotics
  • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
  • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/02—Nasal agents, e.g. decongestants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/08—Antiallergic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
  • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10S435/00—Chemistry: molecular biology and microbiology
  • Y10S435/8215—Microorganisms
  • Y10S435/822—Microorganisms using bacteria or actinomycetales
  • Y10S435/853—Lactobacillus
  • Y10S435/854—Lactobacillus acidophilus

Definitions

• the present invention relates to an anti-aralkyl.
• the present invention also relates to a method for squeezing the allergy for allergies.
• IgE antibodies are added to the Fc ⁇ receptor in the mast cells and blood! You will be deceived by doing. After that, when the sputum is further in the body, the antigen turns into IgE antibody, and the formation of a double “ ⁇ ” causes standing, and the isolated histamine or leukotrien is released. Because of these effects, allergic symptoms are difficult.
• the purpose of the present invention is to reduce the amount of Ig work involved in the onset of type I allergy and to improve the quality of the allergy, forehead, and forehead.
• H and Brelgie « ⁇ is to leave.
• a bacterium that belongs to Lactobacillus acidophilus a bacterium that belongs to Lactobacillus fermentum, and a combination thereof; ⁇ £ * t allergi U is added with the fungus as a component.
• the seasons belonging to Kenji Lactobacillus acidophilus are ratatopathic acidophilus CL0062 strain (if ⁇ fe Depositary Center 3 ⁇ 4 ⁇ ERM BP-4980), CL92 Stock Textile Center, and combinations thereof.
• the frontal rhergi whose seasonal sleep belonging to Lattice Ratatobacillus fermentum is Lactobacillus fermentum CP3 3 ⁇ 4 (characteristic ⁇ 3 ⁇ 4 center ⁇ lii ⁇ fERMBP-8383) is removed.
• the lactic acid bacteria of tif3 ⁇ 43 ⁇ 43 ⁇ 4 in the drug for allergies are selected. Furthermore, according to the present invention, an extreme dose of 3 ⁇ 4 3 ⁇ 4 ! [Allergic U: C @ 1 ⁇ 2t?] Is applied to a carrier who is allergic and needs a strong acupuncture. I'm getting a job for allergies.
• Fig. 1 is a graph showing changes in blood: ⁇ glopurin levels in high IgE mice in Example 1.
• Fig. 2 is a 3 ⁇ 4 ⁇ graph of the results of OVA-IgEiiqiM obtained in Example 2 for a high 3 ⁇ 4 mouse.
• Fig. 3 is a graph 3 ⁇ 4r ⁇ i ⁇ of the experimental results of OVA-IgES ⁇ iJ according to 3 ⁇ 4 "given to high IgE mice in Example 3.
• FIG. 4 is a graph showing the experimental results of OVA-IgE3 ⁇ 4q by male LS in high IgE mice in male example 4.
• Fig. 5 is a graph showing the results of allergic IJ due to human 3 ⁇ 4 "3 ⁇ 4 ⁇ [ ⁇ given in Example 5.
• FIG. 6 is a graph showing the results of allergy ⁇ IJ caused by 3 ⁇ 41 ”3 ⁇ 4 ⁇ L3 ⁇ 4 given to human in Male Example 5.
• the anti-allergic U of the present invention is a group consisting of Lactobacillus acidophilus Lactobacillus acidophilus, Lactobacillus fermentum Lactobacillus fermentum, and combinations thereof. More ⁇ LM as a component
• ratatopathyl acidophilus CL0062 strain As a gonococcus belonging to Lactobacillus acidophilus, ratatopathyl acidophilus CL0062 strain (if $
• Ratatopatylus fermentum CP343 ⁇ 43 ⁇ 4 (% ⁇ All restrictions on fighting potential are imposed by the permission of ⁇ . Also, Ratatopathylus acidophilus CL00623 ⁇ 4 and CL9 ⁇ are currently available to the public.
• Ratatopathic acidophilus CL0062 strain has the following fungi:
• Lactobacillus acidophilus CL92 strain has the following fungal quality. 1) Cell shape: Neisseria gonorrhoeae, 2) Appropriate (presence / absence of live: none, 3) Presence / absence of spores: none
• Ratatopacillus fermentum CP34 has the following fungi:
• the self-season can be determined depending on the amount of i3 ⁇ 4t and the daily dose, but for example, 1 x 10 7 cells / m ! ⁇ 1 X 10 10 cells / ml
• the anti-allergic HI of the present invention can contain other ingredients in addition to acid bacteria.
• examples of other ingredients include leakage of shellfish and the like, and the composition of the medium.
• the anti-allerki of the present invention is
• Any culture medium can be used as long as 13 ⁇ 4 bacteria are viable.
• Animal milk, orchid lewy whey, MRS medium, GA t medium, BL medium, Briggs Liver Broth ⁇ Can use remote areas.
• the culture can be performed for 3 hours at 48 hours, preferably 8 to 12 hours.
• the anti-allergic U of the present invention can be obtained by keeping the medium after completion of the cultivation as it is or by further locking according to the necessity. For example, cells collected from the culture medium after completion of culture by filtration, filtration, etc. to make only the cells, those made «3 ⁇ 4 mulberry cells, and more powerful!
• the fungus ⁇ may also be the anti-allergic U of the present invention. Further, the above-described ones that have been further refined, and those blended with various food materials such as beverages, pastes, breads, and the like can be used as the anti-allergic U of the present invention.
• the administration of the anti-allergic U of the present invention is not particularly restricted, but oral administration is preferred.
• the anti-allergic U of the present invention can effectively suppress the amount of IgE antibody as knitted in a male example, while the fungus that has been sterilized as a food is used as a cocoon component. The completeness seems to be high.
• Allergic of the present invention is to administer dose hate ⁇ ⁇ allergic U to ne ⁇ that requires hard hate: r @ 3 ⁇ 4r ⁇ ? .
• 3 ⁇ 4 ⁇ can be a problem such as pfUi of human and ⁇ : ⁇ ⁇ ya.
• Anti Arerugi U of the present invention while it is possible to reduce the IgE antibody levels in vivo Ko ⁇ , to be » and ⁇ I is high 1 production. Therefore, it is useful for allergies involving IgE antibody levels.
• BALBZc male mice were purchased from Japan Chile Survivane, and CE-2 (Japan Marie Shelf was freed from egg white albumin (hereinafter abbreviated as OVA. Sigma column 10, ag and hydroxylated as Bujuvant)
• OVA egg white albumin
• Aluminum 2 mg sum to 43 ⁇ 4 3 ⁇ 4300 / 1
• OVA which was physiology so that 0VA becomes 25mgZml. Soak the mouse's nose for about 3 seconds f. Turn this operation 3 times at a time, 2 times a day. Do every day until you get a high IgE mouse
• Sandwich ELISA was performed ⁇ 96 well immunoplate (Corningne; t ⁇ ) well, 3 ⁇ 4 mouse IgE polyclonal antibody "Cliff 11", large: 10 ⁇ 1 plus 4 ⁇ "Incubate with C; remove feo plate 3 times with phosphate buffer solution (137 mM NaCl, 2.7 nM KC1, 8. lraM N HP0 4 and 1.5 n 01 ⁇ 0 4 1 ⁇ 2 ⁇ , hereinafter abbreviated as PBS). After addition, 0.5% casein-containing PBS was added to the wells, incubated at room temperature for 3 hours, and thrice-washed with PBS. Add lZ10 ⁇ # 3 ⁇ 4 "with PBS to each well.
• PBS phosphate buffer solution
• the blood of mice given OV Srag / bl ⁇ r ⁇ i ⁇ g ⁇ K 5 times (once / week) is used to decontaminate the serum and use it as a standard serum. If this work fluid is further doubled by * ⁇ ⁇ ⁇ , perform the inspection; explode; If the work fluid on the shelf is Measure the value and obtain sputum Based on this line, calculate the blood serum level (0VA-IgE level is the standard serum O0VA-IgE level is 1).
• mouse P-IgE (plum, casey X). 5 ° / 0 3 ⁇ 4 ⁇ Based on this curve, calculate the total IgE amount in the blood sample
• mice were selected according to the procedure described above, and on day 1 of study, blood 0VA-IgE was measured at a distance from that of Example 1 and the blood OVA-IgE level became low. Allocate the mouse to each of the Cos. For each group of mice, from the 193rd to the 21st day, let each of the above ⁇ , let them be ashamed, 9% Let me be a cunning
• Table 2 ⁇ 3 ⁇ 43 ⁇ 4 ⁇ shows the results of measuring the total number of bacteria during operation feo ⁇ in Example 2 and! In addition, measurement of blood OVA-IgE: results are shown in Fig. 3 ⁇ ; Table 2
• mice were selected according to the procedure of male 1 and sputum, and on the first day, blood OVA-IgE was measured by the measurement method of sputum 1 and sputum on the 8th day.
• the mice were divided into H0 animals so that they would become ⁇ .
• the above 1 « was forcibly administered by lml for 3 days from the 19th to 21st day. : feo consideration 2 on the 2nd day, the B thighs of these mice Then, serum was replenished, and blood OVA-IgE and imigG levels were measured.
• the results are shown in Fig. 4 ⁇ 3 ⁇ 4 ⁇ ⁇ .
• Lactobacillus acidophilus CL92 outline ratatobacillus fermentum CP3 ⁇ ⁇ “Even when fl is administered. OVA-IgE level is significant compared to unimpaired thigh heel On the other hand, no significant lake IJ effect was obtained, and no significant increase was found in the total blood IgG level (Fig. 3 ⁇ 43 ⁇ 4rf).

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Organic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Microbiology (AREA)
• Pulmonology (AREA)
• Mycology (AREA)
• Epidemiology (AREA)
• Molecular Biology (AREA)
• Dermatology (AREA)
• Immunology (AREA)
• Otolaryngology (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Plant Substances (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (13)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=29996753

Family Applications (1)

Country Status (21)

Cited By (3)

Families Citing this family (25)

Citations (11)

Family Cites Families (20)

• 2002
  • 2002-06-26 JP JP2002185897A patent/JP4212838B2/ja not_active Expired - Lifetime
• 2003
  • 2003-06-26 PT PT03738524T patent/PT1555028E/pt unknown
  • 2003-06-26 ES ES03738524T patent/ES2331180T3/es not_active Expired - Lifetime
  • 2003-06-26 WO PCT/JP2003/008094 patent/WO2004002501A1/ja not_active Ceased
  • 2003-06-26 PL PL375158A patent/PL204931B1/pl not_active IP Right Cessation
  • 2003-06-26 DK DK03738524.2T patent/DK1555028T3/da active
  • 2003-06-26 MX MXPA04012636A patent/MXPA04012636A/es active IP Right Grant
  • 2003-06-26 AT AT03738524T patent/ATE444074T1/de not_active IP Right Cessation
  • 2003-06-26 CA CA2490896A patent/CA2490896C/en not_active Expired - Fee Related
  • 2003-06-26 TW TW092117451A patent/TW200402304A/zh not_active IP Right Cessation
  • 2003-06-26 UA UAA200500663A patent/UA86349C2/ru unknown
  • 2003-06-26 US US10/518,801 patent/US20050214270A1/en not_active Abandoned
  • 2003-06-26 KR KR1020087003560A patent/KR20080018287A/ko not_active Ceased
  • 2003-06-26 BR BR0312052-0A patent/BR0312052A/pt not_active IP Right Cessation
  • 2003-06-26 CN CNB038203723A patent/CN100567489C/zh not_active Expired - Lifetime
  • 2003-06-26 DE DE60329516T patent/DE60329516D1/de not_active Expired - Lifetime
  • 2003-06-26 EP EP03738524A patent/EP1555028B1/en not_active Expired - Lifetime
  • 2003-06-26 KR KR1020047020995A patent/KR100836727B1/ko not_active Expired - Lifetime
  • 2003-06-26 AU AU2003246204A patent/AU2003246204B2/en not_active Ceased
  • 2003-06-26 RU RU2005101766/13A patent/RU2336886C2/ru not_active IP Right Cessation
• 2005
  • 2005-01-25 NO NO20050411A patent/NO20050411L/no not_active Application Discontinuation
  • 2005-01-25 ZA ZA200500715A patent/ZA200500715B/xx unknown
• 2008
  • 2008-10-17 US US12/253,819 patent/US8003092B2/en not_active Expired - Lifetime

Patent Citations (11)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events